AT507302T - Process for antibody production - Google Patents

Process for antibody production

Info

Publication number
AT507302T
AT507302T AT05851359T AT05851359T AT507302T AT 507302 T AT507302 T AT 507302T AT 05851359 T AT05851359 T AT 05851359T AT 05851359 T AT05851359 T AT 05851359T AT 507302 T AT507302 T AT 507302T
Authority
AT
Austria
Prior art keywords
process
antibody production
antibody
production
Prior art date
Application number
AT05851359T
Other languages
German (de)
Inventor
Fernando Jose Rebelo Do Couto
Kristin B Hendricks
Stacey Ellen Wallace
Guo-Liang Yu
Original Assignee
Epitomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/984,473 priority Critical patent/US7462697B2/en
Application filed by Epitomics Inc filed Critical Epitomics Inc
Priority to PCT/US2005/039930 priority patent/WO2006050491A2/en
Publication of AT507302T publication Critical patent/AT507302T/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467Igs with modifications in the FR-residues only
AT05851359T 2004-11-08 2005-11-02 Process for antibody production AT507302T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/984,473 US7462697B2 (en) 2004-11-08 2004-11-08 Methods for antibody engineering
PCT/US2005/039930 WO2006050491A2 (en) 2004-11-08 2005-11-02 Methods for antibody engineering

Publications (1)

Publication Number Publication Date
AT507302T true AT507302T (en) 2011-05-15

Family

ID=36316567

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05851359T AT507302T (en) 2004-11-08 2005-11-02 Process for antibody production

Country Status (12)

Country Link
US (5) US7462697B2 (en)
EP (1) EP1819830B1 (en)
JP (2) JP2008518619A (en)
CN (2) CN103980362A (en)
AT (1) AT507302T (en)
CA (2) CA2901238A1 (en)
DE (1) DE602005027737D1 (en)
DK (1) DK1819830T3 (en)
ES (1) ES2362792T3 (en)
HK (1) HK1200854A1 (en)
PT (1) PT1819830E (en)
WO (1) WO2006050491A2 (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
MX343879B (en) * 2007-05-21 2016-11-25 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies.
CN101600793B (en) * 2006-05-19 2013-06-26 奥尔德生物制药公司 Culture method for obtaining a clonal population of antigen-specific b cells
US8280711B2 (en) 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
AU2013204593B2 (en) * 2007-05-21 2016-01-21 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
TW201531484A (en) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc Antibodies to TNF alpha and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
NZ581596A (en) * 2007-05-21 2012-02-24 Alderbio Holdings Llc Antibodies to il-6 and use thereof
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
CN102838673B (en) * 2007-06-25 2016-05-11 艾斯巴技术-诺华有限责任公司 The method of modified antibodies and there is the modified antibodies of functional character of improvement
BRPI0813287A2 (en) * 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Planning and optimization based on the sequence of single chain antibodies
CA2695484C (en) * 2007-08-20 2018-05-01 Glaxo Group Limited Production method of therapeutic proteins based on codon adaptation
PL2202245T3 (en) * 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
US7803371B2 (en) * 2008-03-26 2010-09-28 Epitomics, Inc. Anti-VEGF antibody
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
WO2011066378A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat thrombosis
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
PT2307454T (en) * 2008-06-25 2017-04-26 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies inhibiting vegf
PL2307457T3 (en) * 2008-06-25 2018-11-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting tnf
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2414396B1 (en) 2009-03-30 2015-02-25 Edimer Biotech S.a. Preparation of isolated agonist anti-edar monoclonal antibodies
ES2495367T3 (en) 2009-04-29 2014-09-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
CN102002104A (en) 2009-08-28 2011-04-06 宜康公司 Anti-VEGF monoclonal antibody and medicinal composition containing same
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
PL2509409T3 (en) 2009-12-10 2017-02-28 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
CA2782578C (en) 2009-12-22 2019-03-05 F. Hoffmann-La Roche Ag Sequence dependent aggregation
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
CN101928345B (en) * 2010-06-21 2012-08-29 中国科学技术大学 Human source antibody and humanization remolding method thereof
CN103328511B (en) * 2010-09-10 2016-01-20 埃派斯进有限公司 Anti-IL-1 β antibody and using method thereof
TWI452135B (en) 2010-11-17 2014-09-11 Chugai Pharmaceutical Co Ltd A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2643018A4 (en) 2010-11-23 2016-06-29 Alderbio Holdings Llc Anti-il-6 antibodies for the treatment of oral mucositis
AU2012223449A1 (en) 2011-03-03 2013-05-02 Apexigen, Inc. Anti-IL-6 receptor antibodies and methods of use
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
SG194701A1 (en) 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
CN103732621A (en) * 2011-05-06 2014-04-16 Nvip私人有限公司 Anti-nerve growth factor antibodies and methods of preparing and using the same
PT2717917T (en) 2011-07-05 2016-07-27 Bioasis Tech Inc P97-antibody conjugates
EP2732269B1 (en) 2011-07-12 2017-10-18 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
PL2739649T3 (en) 2011-08-05 2018-03-30 Bioasis Technologies Inc. Fragmenty p97 o aktywności transferowej
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
US9988687B2 (en) 2011-09-20 2018-06-05 The George Washington Univeristy Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants
KR102027603B1 (en) 2011-11-02 2019-10-01 아펙시젠, 인코포레이티드 Anti-kdr antibodies and methods of use
WO2013130565A1 (en) * 2012-02-29 2013-09-06 The Brigham And Women's Hosptial, Inc. Neutralizing antibody for epstein barr virus associated disease
WO2014070934A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
JP2016500367A (en) * 2012-12-05 2016-01-12 デュタリス ゲーエムベーハー Dual targeting
CN103145834B (en) * 2013-01-17 2015-03-18 广州泰诺迪生物科技有限公司 Antibody humanization transformation method
BR112015022416A2 (en) 2013-03-13 2017-10-24 Bioasis Tech Inc p97 fragments and their uses
EP2970462A4 (en) 2013-03-14 2017-02-22 Apexigen, Inc. Anti-rankl antibodies and methods of use
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015026606A1 (en) 2013-08-19 2015-02-26 Epitomics, Inc. Antibody identification by lineage analysis
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
SI3071595T1 (en) * 2013-11-19 2019-08-30 Fredax Ab Humanised anti kallikrein-2 antibody
MX2016007123A (en) 2013-12-03 2017-02-15 Harvard College Methods and reagents for the assessment of gestational diabetes.
EP3094976A4 (en) 2014-01-17 2017-07-05 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
DK3107562T3 (en) 2014-02-19 2019-12-16 Bioasis Tech Inc P97-ids fusion protein
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
CA2943890A1 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
SG10201800851XA (en) 2014-09-26 2018-03-28 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
KR101618458B1 (en) 2014-11-28 2016-05-10 강원대학교산학협력단 Method for Obtaining Information of Amino Acid Sequence in Antibody Having the Positive Correlation with Antigen-Antibody Binding Strength
SG11201607165YA (en) 2014-12-19 2016-09-29 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
RU2017123731A3 (en) 2014-12-19 2019-12-02
GB201500464D0 (en) 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
KR20170110129A (en) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use
AU2016218983A1 (en) 2015-02-13 2017-08-10 Biommune Technologies Inc. Antibodies to L-type voltage gated channels and related methods
EP3494143A2 (en) 2016-08-03 2019-06-12 Achaogen, Inc. Plazomicin antibodies and methods of use
TW201833140A (en) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 Anti-fgfr antibodies and methods of use
WO2019233984A1 (en) 2018-06-08 2019-12-12 Ventana Medical Systems, Inc. Universal or normalized antibody frameworks for improved functionality and manufacturability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6093853A (en) * 1997-07-04 2000-07-25 Nok Corporation Phenylenediamine derivative, production method thereof and antioxidant for rubber using it as effective constituent
US6342587B1 (en) * 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US7115716B2 (en) * 2001-11-19 2006-10-03 Eli Lilly And Company Tumor specific monoclonal antibodies
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
CA2483848C (en) * 2002-04-30 2012-08-21 Kyowa Hakko Kogyo Co., Ltd. Antibody against human insulin-like growth factor
US20040086979A1 (en) * 2002-08-15 2004-05-06 Dongxiao Zhang Humanized rabbit antibodies
PT1748074E (en) * 2003-01-17 2012-01-16 Danisco Method for the in situ production of an emulsifier in a foodstuff
CA2516455C (en) * 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP1599606A1 (en) * 2003-03-03 2005-11-30 Arizona Board of Regents on behalf of The University of Arizona Protein tyrosine phosphatase - prl-1 a a marker and therapeutic target for pancreatic cancer
US20050033031A1 (en) * 2003-08-07 2005-02-10 Couto Fernando Jose Rebelo Do Methods for humanizing rabbit monoclonal antibodies
US8148335B2 (en) * 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering

Also Published As

Publication number Publication date
US7960517B2 (en) 2011-06-14
US7462697B2 (en) 2008-12-09
US20150038370A1 (en) 2015-02-05
EP1819830B1 (en) 2011-04-27
HK1200854A1 (en) 2015-08-14
CA2585742C (en) 2016-04-12
US20060099204A1 (en) 2006-05-11
US8404816B2 (en) 2013-03-26
PT1819830E (en) 2011-07-20
DK1819830T3 (en) 2011-07-04
DE602005027737D1 (en) 2011-06-09
CA2901238A1 (en) 2006-05-11
ES2362792T3 (en) 2011-07-13
US20120329069A1 (en) 2012-12-27
CN101080496A (en) 2007-11-28
WO2006050491A3 (en) 2006-12-28
JP5096611B2 (en) 2012-12-12
EP1819830A4 (en) 2009-03-11
JP2008518619A (en) 2008-06-05
WO2006050491A2 (en) 2006-05-11
JP2012095654A (en) 2012-05-24
CA2585742A1 (en) 2006-05-11
CN103980362A (en) 2014-08-13
EP1819830A2 (en) 2007-08-22
US20090155824A1 (en) 2009-06-18
US20120003671A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
DK1937721T3 (en) Anti-IL-23 antibodies
DK1889059T3 (en) Method for Enhanced Immunoassay
FR2865731B1 (en) Process for producing a hydrofluoroalcan
DK1681337T3 (en) Process for the production of hydrocarbons
DK1795576T3 (en) Process for the production of hydrocarbons
DK1751296T3 (en) Process for producing ethanol
AT516816T (en) Process for the production of vaccines
AT483043T (en) Process for growing gan-einkristallen
AT523053T (en) Process for increasing position availability
AT551631T (en) Molding process for structure manufacturing
AT479409T (en) Process for producing sucking core
DE602004001213D1 (en) Process for the production of polyethylene
DE602004025805D1 (en) Method for the production of antibodies
RU2006136084A (en) Method for producing microcyclic compounds
AT527315T (en) Method for the production of transparent form bodies
DE602006020386D1 (en) Duraimplantat and method for its production
RU2005118310A (en) Method for making kvass
DE502005002302D1 (en) Process for the production of panels
RU2005120102A (en) METHOD FOR PRODUCING INTEGRATED biosensors
AT488626T (en) Process for producing elastic webstuffs
RU2007125710A (en) METHOD FOR PRODUCING N-Phenylpyrazole-1-carboxamides
AT511978T (en) Method for producing blash-molded containers
DE502004005538D1 (en) Process for the production of shoes
DE602005016292D1 (en) Process for the production of glatiramer
AT486077T (en) Method for producing maytansinoidesters

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties